224 related articles for article (PubMed ID: 35499850)
21. Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome.
Besag FMC; Vasey MJ; Chin RFM
Expert Opin Pharmacother; 2023; 24(11):1249-1268. PubMed ID: 37212330
[TBL] [Abstract][Full Text] [Related]
22. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years.
Conry JA; Ng YT; Kernitsky L; Mitchell WG; Veidemanis R; Drummond R; Isojarvi J; Lee D; Paolicchi JM;
Epilepsia; 2014 Apr; 55(4):558-67. PubMed ID: 24580023
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.
Lattanzi S; Brigo F; Cagnetti C; Trinka E; Silvestrini M
CNS Drugs; 2018 Oct; 32(10):905-916. PubMed ID: 30132269
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial.
Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K
Epilepsy Res; 2016 Mar; 121():1-7. PubMed ID: 26827266
[TBL] [Abstract][Full Text] [Related]
25. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.
Glauser T; Kluger G; Sachdeo R; Krauss G; Perdomo C; Arroyo S
Neurology; 2008 May; 70(21):1950-8. PubMed ID: 18401024
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
Zhang L; Li W; Wang C
Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
[TBL] [Abstract][Full Text] [Related]
27. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.
French JA; Porter RJ; Perucca E; Brodie MJ; Rogawski MA; Pimstone S; Aycardi E; Harden C; Qian J; Rosenblut CL; Kenney C; Beatch GN;
JAMA Neurol; 2023 Nov; 80(11):1145-1154. PubMed ID: 37812429
[TBL] [Abstract][Full Text] [Related]
29. Seizure-free days as a novel outcome in patients with Lennox-Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials.
Auvin S; Nortvedt C; Fuller DS; Sahebkar F
Epilepsia; 2023 Jul; 64(7):1812-1820. PubMed ID: 37052803
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
Knight EMP; Amin S; Bahi-Buisson N; Benke TA; Cross JH; Demarest ST; Olson HE; Specchio N; Fleming TR; Aimetti AA; Gasior M; Devinsky O;
Lancet Neurol; 2022 May; 21(5):417-427. PubMed ID: 35429480
[TBL] [Abstract][Full Text] [Related]
31. What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice.
Valls Carbó A; Beltrán Á; Sánchez-Miranda Román I; Cabal B; Gómez-Porro P; Aledo-Serrano Á; López Sobrino G; Ayuga F; Gómez Eguilaz M; Gil-Nagel A
Epilepsy Behav; 2024 Feb; 151():109620. PubMed ID: 38194770
[TBL] [Abstract][Full Text] [Related]
32. Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial.
Sullivan J; Lagae L; Cross JH; Devinsky O; Guerrini R; Knupp KG; Laux L; Nikanorova M; Polster T; Talwar D; Ceulemans B; Nabbout R; Farfel GM; Galer BS; Gammaitoni AR; Lock M; Agarwal A; Scheffer IE;
Epilepsia; 2023 Oct; 64(10):2653-2666. PubMed ID: 37543865
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
[TBL] [Abstract][Full Text] [Related]
34. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
[TBL] [Abstract][Full Text] [Related]
35. Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open-label exploratory trial.
Auvin S; Arzimanoglou A; Beller C; Floricel F; Daniels T; Bozorg A
Epilepsia; 2023 Nov; 64(11):2947-2957. PubMed ID: 37545406
[TBL] [Abstract][Full Text] [Related]
36. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome.
Ng YT; Conry JA; Drummond R; Stolle J; Weinberg MA;
Neurology; 2011 Oct; 77(15):1473-81. PubMed ID: 21956725
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: A post hoc analysis from Study 022.
Arzimanoglou A; Pringsheim M; Kluger GJ; Genton P; Perdomo C; Malhotra M
Epilepsy Behav; 2021 Sep; 124():108275. PubMed ID: 34509883
[TBL] [Abstract][Full Text] [Related]
38. Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials.
Privitera M; Bhathal H; Wong M; Cross JH; Wirrell E; Marsh ED; Mazurkiewicz-Beldzinska M; Villanueva V; Checketts D; Knappertz V; VanLandingham K
Epilepsia; 2021 May; 62(5):1130-1140. PubMed ID: 33797076
[TBL] [Abstract][Full Text] [Related]
39. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
[TBL] [Abstract][Full Text] [Related]
40. Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study.
Nikanorova M; Brandt C; Auvin S; McMurray R
Epilepsy Behav; 2017 Nov; 76():63-70. PubMed ID: 28927712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
